TOPIC

New medical drugs

New medical drugs
Latest news and updates on medical drug research and breakthroughs.
China is gaining a solid reputation as a pharmaceutical innovation hub, according to global consultancy Idea Pharma. Photo: AP
Made in China 2025

China’s pharmaceutical industry transforms into a global innovation powerhouse

The China Pharmaceutical Innovation and Invention Index, a new gauge, highlights top drug makers on the mainland for the first time.

Science

Sperm quality decline: could easy-to-use balm from China solve the crisis?

videocam
China economy

Opinion | How China engineered the rapid rise of its drug innovation industry

videocam
Hansoh Pharmaceutical

6 of the best: the billion-dollar biotechs putting China on the map

China’s biotech renaissance is gathering pace as home-grown innovators strike billion-dollar licensing deals with global giants.

Illustration: Henry Wong
China’s private sector

Fosun brings UK particle therapy to mainland China in advanced cancer care push

The US Food and Drug Administration-approved Marie system promises human-centred care, advanced technology and lower costs.

Biomedicine: Companies

China biotech forum bills antibody cancer drugs as next-generation treatment

Biotech insiders tout antibody-drug conjugates as the next big thing in cancer treatment, with firms urged to pursue global strategies.

Advertisement
Advertisement
Advertisement
Hong Kong stock market

China’s Akeso gets share boost as data shows cancer drug’s benefits

Lung-cancer drug ivonescimab is ‘potentially two to three years ahead of competitors’, analyst says.

Trial showed “a decisive and strong positive outcome with both significant and clinically meaningful benefits”, Akeso said. Photo: Shutterstock
Biomedicine: Companies

Hansoh and Leads Biolabs clinch US$2.5 billion in global drug licensing deals

Two mainland biotech firms win global attention as Roche and Dianthus sign major licensing pacts, highlighting China’s growing role in next-generation drug development.

Mergers & Acquisitions

CK Life unit merges with TransCode as Li Ka-shing firm eyes anticancer drugs

Upon completion of the transaction, CK Life will own about 9.1 per cent of TransCode’s outstanding common shares.

Health & Fitness

Li Ka-shing-backed focused ultrasound therapy treats 1 millionth case

The therapy, which uses ultrasound energy to treat a number of diseases including cancer, is gaining global traction, a US expert says.

Minnesota-based HistoSonics makes focused ultrasound machines for treating liver tumours. Photo: Handout
United States

China’s pharmaceutical sector surges amid growth in sales, licensing income

Strong growth momentum and global push expected to continue, HSBC says.

Chinese pharmaceutical companies’ licensing deals made up about 50 per cent of the total value of such transactions worldwide in the first eight months of the year. Photo: Shutterstock
Biomedicine: Industry Trends

China’s drug developers stretch to become a global force

Although a start-up’s recent triumph is seen as a ‘DeepSeek moment’, domestic players still trail world-beating pharma firms, experts say.

10
IPO

Chinese healthcare, biotech firms flock to Hong Kong for IPOs

September yields at least 23 listing applications from mainland biotech firms eyeing the city’s lucrative fundraising market.

Biomedicine: Companies

Pfizer’s Metsera acquisition to spur Chinese search for new weight drugs

The deal, worth up to US$7.3 billion, will encourage ongoing investment by mainland players but not draw in new rivals, analysts say.

The Pfizer deal is not good news for Chinese firms developing weight-loss drugs with the aim of reducing injections, an analyst says. Photo: Shutterstock
Biomedicine: Companies

China’s Hengrui gets boost from fifth drug-licensing deal of year

Shares rise after Mumbai-based Glenmark Pharmaceuticals strikes deal for cancer drug.

A worker checks a machine at Hengrui Biomedical Industrial Park in Lianyungang, in East China’s Jiangsu province, on December 13, 2021. Photo: Future Publishing via Getty Images
US-China relations

Opinion | Why US-China health and drugs cooperation must top Trump-Xi agenda

The years-long impasse harms both nations and the world, and the stakes in global health security could not be higher.

videocam
Health in China

Beijing tackles drug price wars with new tendering rules in anti-involution push

China’s new drug procurement rules prioritise quality over price in a bid to curb cutthroat competition.

Advertisement
Advertisement
Advertisement
Biomedicine: Companies

Ascletis trial shows drug candidate ASC47 boosts semaglutide weight loss effect

Chinese biotech firm is among dozens of mainland drug makers seeking to compete in the global market for diabetes and weight-loss drugs.

China’s weight-loss drugs market could grow to US$5.6 billion in 2035, according to Goldman Sachs. Photo: Shutterstock
Fosun Group

Fosun’s Henlius in talks with Johnson & Johnson, Roche on cancer drug

Shanghai Henlius Biotech is in talks with multinational pharmaceutical firms about selling them the rights to an experimental cancer drug.

China technology

China’s biotech industry is gaining on the US. Can tariffs hold them back?

Pharmaceutical firms in China have grown fast, but geopolitics and a long head start could keep US-based leaders at industry apex - for now.

videocam
China Future Tech briefing

Biomedicine | China goes big on weight-loss drugs in Novo, Eli Lilly challenge

Demand for anti-obesity drugs has expanded along with people’s waistlines, and Chinese companies are seeking to cash in with new treatments.

videocam
China goes big on weight-loss drugs in Novo, Eli Lilly challenge
Biomedicine: Companies

Chinese pharma firms Hengrui, Hansoh expected to post strong first-half profits

Novel drug roll-outs and revenue from licensing buoy results.

Workers inside Hansoh Pharmaceutical. Photo: Handout
Biomedicine: Companies

China’s biomedicine sector takes off

China’s novel drug industry is experiencing a meteoric rise, fuelled by the increased development of new medicines and the prospect of many patents expiring.

Biomedicine: Companies

Chinese drug developer XTalPi surges on US$6 billion deal

Deal with DoveTree, established by Harvard professor Gregory Verdine, adds to growing list of licensing tie-ups with Chinese firms.

Biomedicine: Companies

Chinese drug start-ups poised for 2025 profits, in industry milestone

Innovent likely to post a first-half net profit of US$36.4 million, and BeOne’s first-half net profit is expected to come in at US$42 million.

A close-up shot of a microscope in a laboratory. Photo: Shutterstock
Banking & finance

Wuxi AppTec joins funding rush as appetite grows for China’s biotech

WuxiAppTec raised HK$7.70 billion (US$981 million) in a sale of additional shares to fund its global expansion.

Wuxi AppTec’s research center in Shanghai on June 6, 2023. Photo: Getty Images
Biomedicine: Companies

GSK to pay Hengrui US$12.5 billion for global rights to 12 drug projects

The deal would give GSK the rights to develop the drug for HRS-9821 and 11 preclinical programmes owned by Jiangsu Hengrui Pharmaceuticals.

4
Biomedicine: Companies

Pfizer, Chinese biotech firm 3SBio complete licensing deal for cancer drug

Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity investment in 3SBio.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement